News summary

Protego Presents New Data at ISA 2026 that Advances Evidence for Light-Chain Stabilization with PROT-001 in AL Amyloidosis

Source: PR Newswire • Published: 16 Nov 2026, 12:01

Summarized by Masters of Longevity from PR Newswire.

Phase 1 data show PROT-001 was tolerated and stabilized amyloidogenic lambda light chains.

Protego Presents New Data at ISA 2026 that Advances Evidence for Light-Chain Stabilization with PROT-001 in AL Amyloidosis
Key Takeaways
  • PROT-001 was generally safe and reached stabilizing plasma levels.
  • PROT-001 reduced BNP and troponin in cardiomyocyte tests.
  • Early NT-proBNP reductions were reported within 28 days.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.MoL PickFrom Metrics to Better LivingEverstride’s May 2026 Consumer Health Market Briefing shows a wellness market moving from products to systems, from tracking to guidance, and from optimization to meaning. The next winners in longevity may not be the companies that measure the most. They may be the ones that help consumers translate health data into a life they actually want to live.